TB-500

Mechanism of action

TB-500 is the commercial designation for a synthetic peptide derived from residues 17 to 23 of thymosin beta-4 (Tβ4), encompassing the sequence Leu-Lys-Lys-Thr-Glu-Thr-Gln. This heptapeptide contains the principal G-actin-binding motif of the full 43-amino-acid parent protein — specifically the LKKTET sequence that interacts with subdomain 1 of monomeric actin. By binding and sequestering cytoplasmic G-actin, TB-500 influences the dynamic equilibrium between monomeric and filamentous actin (the G-F actin ratio), which in turn governs cytoskeletal organisation, cell polarity, and migratory capacity. This mechanism positions TB-500 as a promoter of directed cell migration — a prerequisite for wound closure, tendon-fibroblast infiltration, and vascular ingrowth. Upstream of cytoskeletal effects, TB-500 is reported to upregulate vascular endothelial growth factor (VEGF) expression in several cell-culture and tissue models. Increased VEGF promotes angiogenesis and endothelial proliferation, contributing to the neovascularisation that underpins the accelerated wound closure observed in murine full-thickness wound experiments (Malinda K.M. et al., FASEB J, 1999; 2003). Laminin-5, a basement-membrane glycoprotein that anchors epithelial cells and promotes keratinocyte migration, is also reported to be upregulated in TB-500-treated wound beds. Anti-inflammatory activity has been attributed to suppression of the NF-κB signalling pathway in inflammatory-cell populations. Reduced nuclear translocation of NF-κB p65 has been observed in lipopolysaccharide-stimulated macrophages exposed to full-length Tβ4 and its central fragment, with consequent reductions in TNF-α, IL-1β, and IL-6 secretion. This anti-inflammatory profile complements rather than replaces the reparative effects: dampening the destructive early inflammatory phase accelerates the transition to proliferative healing. In cardiac tissue, full-length Tβ4 has been demonstrated to mobilise dormant epicardial progenitor cells following myocardial ischaemia (Smart N. et al., Nature, 2007; PMID 17554319). Whether the shorter TB-500 fragment recapitulates this progenitor-mobilisation effect is not clearly established; most cardiac-regeneration research uses the full-length protein, and researchers should interpret marketed TB-500 cardiac claims with appropriate caution. Batch identity is a critical interpretive variable for TB-500 research. Commercial preparations vary considerably in peptide length and purity. Some preparations contain the full-length 43-amino-acid Tβ4 molecule, others the LKKTETQ heptapeptide, and yet others are mixtures. Independent mass-spectrometry verification is strongly recommended before attributing experimental outcomes to a specific molecular species.

The seven-amino-acid LKKTETQ actin-binding motif of thymosin beta-4 retains the full endothelial cell-migration activity of the 43-amino-acid parent protein, providing the mechanistic basis for TB-500 as a fragment-based research compound.

— Notable finding

Research history

Thymosin beta-4 was originally isolated from calf thymus tissue in 1981 by Allan Goldstein and colleagues at the National Institutes of Health, who characterised it as a thymic hormone involved in T-lymphocyte maturation. Subsequent biochemical studies in the 1990s revealed that the protein is not thymus-specific at all but is instead one of the most abundantly expressed intracellular proteins in mammalian cells — essentially wherever cytoskeletal dynamics are required, Tβ4 is present. The discovery that the LKKTET motif within Tβ4 was the minimal sequence necessary for actin binding was made during structure-function studies in the early-to-mid 1990s and was foundational to the concept of fragment-based peptide therapy. The commercial designation 'TB-500' entered the research-chemical marketplace in the early 2000s, originally in the context of equine veterinary medicine, where the compound was used by trainers in horse-racing to manage tendon injuries. This equine origin remains closely associated with the compound and explains some of the observational literature from veterinary sports medicine. Meanwhile, RegeneRx Biopharmaceuticals advanced full-length recombinant Tβ4 (as RGN-352) into Phase I and II human trials for acute myocardial infarction and (as RGN-259 ophthalmic drops) for neurotrophic keratitis and dry-eye disease. These programmes established that human exposure to exogenous Tβ4 is generally safe in the short term and provided the first pharmacokinetic data for the full-length molecule in humans. Results in cardiac applications were mixed; the corneal application has produced the strongest clinical signals.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Animal studies of both TB-500 (the fragment) and full-length thymosin beta-4 have reported a favourable acute toxicity profile across multiple species and routes of administration. Repeat-dose rodent studies at pharmacologically relevant doses have not revealed organ-level pathology on routine histopathology. Phase I human data from intravenous full-length Tβ4 (RGN-352, RegeneRx) confirmed no dose-limiting toxicities at doses tested. The principal safety uncertainties for TB-500 specifically are batch composition and long-term immunogenicity. Preparations mislabelled as 'TB-500' may contain full-length Tβ4, the LKKTETQ fragment, or other thymosin-related peptides in varying proportions. The immunogenic potential of repeated exogenous peptide administration — including possible anti-drug antibody formation — has not been systematically evaluated for the fragment. Pro-angiogenic activity, as with BPC-157, raises a theoretical consideration in neoplastic models. No tumour-promotion findings have been reported in the available literature. For laboratory preparations, the standard quality caveats apply: HPLC purity ≥98%, mass-spectrometry identity confirmation, and endotoxin testing (LAL assay, <1 EU/mg) are the minimum requirements for any injectable research preparation. Sterility must be confirmed by standard membrane-filtration or direct-inoculation methods.

UK regulatory status

TB-500 is not licensed as a medicine by the MHRA and has no marketing authorisation in the United Kingdom. The compound has not undergone the clinical development required for product licensing; its use in the UK is strictly restricted to in-vitro and in-vivo pre-clinical laboratory research. For competitive athletes, TB-500 is prohibited under the World Anti-Doping Agency Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). This prohibition applies both in-competition and out-of-competition and encompasses all forms and formulations of thymosin beta-4 and its fragments. Athletes who use TB-500 for any purpose risk anti-doping rule violations. Veterinary use in the UK is likewise unlicensed for TB-500 specifically, although related research into thymosin-family proteins has been conducted in equine sports medicine contexts. No specific UK enforcement actions relating to TB-500 as a research chemical are recorded in the public domain.

Frequently asked questions